1. Home
  2. ZNTL vs NODK Comparison

ZNTL vs NODK Comparison

Compare ZNTL & NODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • NODK
  • Stock Information
  • Founded
  • ZNTL 2014
  • NODK 1946
  • Country
  • ZNTL United States
  • NODK United States
  • Employees
  • ZNTL N/A
  • NODK N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • NODK Property-Casualty Insurers
  • Sector
  • ZNTL Health Care
  • NODK Finance
  • Exchange
  • ZNTL Nasdaq
  • NODK Nasdaq
  • Market Cap
  • ZNTL 300.4M
  • NODK 309.4M
  • IPO Year
  • ZNTL 2020
  • NODK 2017
  • Fundamental
  • Price
  • ZNTL $3.70
  • NODK $15.60
  • Analyst Decision
  • ZNTL Buy
  • NODK
  • Analyst Count
  • ZNTL 7
  • NODK 0
  • Target Price
  • ZNTL $13.14
  • NODK N/A
  • AVG Volume (30 Days)
  • ZNTL 1.6M
  • NODK 17.5K
  • Earning Date
  • ZNTL 08-07-2024
  • NODK 08-06-2024
  • Dividend Yield
  • ZNTL N/A
  • NODK N/A
  • EPS Growth
  • ZNTL N/A
  • NODK N/A
  • EPS
  • ZNTL N/A
  • NODK 0.24
  • Revenue
  • ZNTL $40,560,000.00
  • NODK $375,489,000.00
  • Revenue This Year
  • ZNTL N/A
  • NODK N/A
  • Revenue Next Year
  • ZNTL N/A
  • NODK N/A
  • P/E Ratio
  • ZNTL N/A
  • NODK $66.83
  • Revenue Growth
  • ZNTL N/A
  • NODK 10.49
  • 52 Week Low
  • ZNTL $3.27
  • NODK $12.01
  • 52 Week High
  • ZNTL $29.03
  • NODK $16.55
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 30.12
  • NODK 55.95
  • Support Level
  • ZNTL $3.83
  • NODK $14.89
  • Resistance Level
  • ZNTL $4.79
  • NODK $16.10
  • Average True Range (ATR)
  • ZNTL 0.44
  • NODK 0.24
  • MACD
  • ZNTL 0.26
  • NODK 0.09
  • Stochastic Oscillator
  • ZNTL 28.29
  • NODK 62.96

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About NODK NI Holdings Inc.

NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.

Share on Social Networks: